ANEBULO PHARMAC INC by Anebulo Pharmaceuticals Inc Analyst Price Targets - Benzinga

SPY752.88+0.10%QQQ682.55+0.21%BTC/USD76,802.31+0.17%DIA519.00−0.07%GLD362.74+0.30%TLT81.61−0.15%

Premium Services

ANEBULO PHARMAC INC by Anebulo Pharmaceuticals Inc

ANEBOTCEM

Trade with Public

Trade with Public

$0.3295

-0.0305-8.47%

Last update: Jul 21, 9:25 AM

Overview News Earnings ForecastPrice TargetsFinancials Sentiment Ownership Compare

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

ANEBULO PHARMAC INC by Anebulo Pharmaceuticals Inc Analyst Price Targets

Wall Street analyst price targets and consensus rating for ANEBULO PHARMAC INC by Anebulo Pharmaceuticals Inc (ANEB).

Price Target Range — 2 Quarters

Analyst Consensus — 1 Analysts

1Hold

Consensus RatingSpeculative Buy# Analysts1Avg. Consensus PT$8Upside to Avg. PT+2327.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 23, 2025	Maxim Group	Michael Okunewitch	Downgrade	Buy→Hold	—
May 15, 2025	Maxim Group	Michael Okunewitch	PT Cut	Buy	$6→$3
Nov 19, 2024	Benchmark	Robert Wasserman	Maintained	Speculative Buy	$8
Oct 1, 2024	Benchmark	Robert Wasserman	Maintained	Speculative Buy	$8

Analyst Ratings News

PRO
Maxim Group Downgrades Anebulo Pharmaceuticals to Hold

Maxim Group analyst Michael Okunewitch downgrades Anebulo Pharmaceuticals (NASDAQ:ANEB) from Buy to Hold.

Benzinga Newsdesk

PRO
Maxim Group Maintains Buy on Anebulo Pharmaceuticals, Lowers Price Target to $3

Maxim Group analyst Michael Okunewitch maintains Anebulo Pharmaceuticals (NASDAQ:ANEB) with a Buy and lowers the price target from $6 to $3.

Benzinga Newsdesk

PRO
Benchmark Reiterates Speculative Buy on Anebulo Pharmaceuticals, Maintains $8 Price Target

Benchmark analyst Robert Wasserman reiterates Anebulo Pharmaceuticals (NASDAQ:ANEB) with a Speculative Buy and maintains $8 price target.

Benzinga Newsdesk

PRO
Benchmark Reiterates Speculative Buy on Anebulo Pharmaceuticals, Maintains $8 Price Target

Benchmark analyst Robert Wasserman reiterates Anebulo Pharmaceuticals (NASDAQ:ANEB) with a Speculative Buy and maintains $8 price target.

Benzinga Newsdesk

PRO
Benchmark Reiterates Speculative Buy on Anebulo Pharmaceuticals, Maintains $8 Price Target

Benchmark analyst Robert Wasserman reiterates Anebulo Pharmaceuticals (NASDAQ:ANEB) with a Speculative Buy and maintains $8 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Anebulo Pharmaceuticals, Maintains $6 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Anebulo Pharmaceuticals (NASDAQ:ANEB) with a Buy and maintains $6 price target.

Benzinga Newsdesk